Article

Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy.

Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20852, USA.
British Journal of Haematology (Impact Factor: 4.96). 07/2010; 150(2):196-9. DOI: 10.1111/j.1365-2141.2010.08216.x
Source: PubMed

ABSTRACT In severe congenital neutropenia (SCN), long-term therapy with granulocyte colony-stimulating factor (G-CSF) has reduced mortality from sepsis, revealing an underlying predisposition to myelodysplastic syndrome and acute myeloid leukaemia (MDS/AML). We have reported the early pattern of evolution to MDS/AML, but the long-term risk remains uncertain. We updated a prospective study of 374 SCN patients on long-term G-CSF enrolled in the Severe Chronic Neutropenia International Registry. Long-term, the annual risk of MDS/AML attained a plateau (2.3%/year after 10 years). This risk now appears similar to, rather than higher than, the risk of AML in Fanconi anaemia and dyskeratosis congenita.

1 Follower
 · 
163 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: G-CSF was among the first cytokines to be identified and rapidly transitioned into clinical medicine. Initially used to promote the production of neutrophils in patients with chemotherapy-induced neutropenia it helped to revolutionize the delivery of cancer therapy. Its ability to mobilize hematopoietic stem cells from the bone marrow into the blood was subsequently exploited, changing the face of hematopoietic stem cell transplantation. Today the knowledge gained in unraveling the mechanisms of stem cell mobilization by G-CSF is being explored as a means to increase chemosensitivity in hematological malignancies. This review provides a brief history of G-CSF and then focuses on recent advances in our understanding of G-CSF-induced stem cell mobilization and the potential clinical application of this knowledge in chemo-sensitization.
    Cytokine & Growth Factor Reviews 08/2014; 25(4). DOI:10.1016/j.cytogfr.2014.07.011 · 6.54 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The inherited bone marrow failure syndromes are a diverse group of genetic diseases associated with inadequate production of one or more blood cell lineages. Examples include Fanconi anemia, dyskeratosis congenita, Diamond-Blackfan anemia, thrombocytopenia absent radii syndrome, severe congenital neutropenia, and Shwachman-Diamond syndrome. The management of these disorders was once the exclusive domain of pediatric subspecialists, but increasingly physicians who care for adults are being called upon to diagnose or treat these conditions. Through a series of patient vignettes, we highlight the clinical manifestations of inherited bone marrow failure syndromes in adolescents and young adults. The diagnostic and therapeutic challenges posed by these diseases are discussed.
    Annals of Medicine 06/2014; DOI:10.3109/07853890.2014.915579 · 4.73 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: The identification, purification and molecular cloning of granulocyte colony-stimulating factor G-CSF in the 1980s; the nonclinical studies in the mid-1980s; and the subsequent development of G-CSF as a therapeutic agent in the late 1980s and 1990s have had a major influence on the treatment of many diseases. In the clinical setting, filgrastim and lenograstim are of benefit to patients receiving chemotherapy or myeloablative treatment. They have been shown to reduce morbidity and mortality in many patient populations. Stem cell transplantation using G-CSF-mobilised peripheral-blood stem cells revolutionised stem cell transplantation, making it simpler, more efficient and more widely applicable in the clinic. Areas covered: This review discusses the development and clinical uses of filgrastim, lenograstim and other biosimilar G-CSFs. Expert opinion: In the next few years, the economics of G-CSF may even change with the introduction of biosimilars. Initial concerns about the use of biosimilar G-CSFs, appear to be unfounded. Adoption of cost-effective biosimilars should help reduce healthcare costs and improve patient access to biological treatments.
    Expert opinion on biological therapy 04/2014; DOI:10.1517/14712598.2014.905537 · 3.65 Impact Factor

Preview

Download
0 Downloads
Available from